Interventions for preventing osteoporosis in women on heparin therapy during pregnancy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Abdollahi, Mohammad ^a   Nikfar, Shekoufeh ^a   Hosseini Tabatabaei, Azadeh ^b   Rezaie, Ali ^c   Kellie, Frances J ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 85041836340     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008547.pub2     Document Type: Article

References (37)

1. Arfvidsson B, Eklof B, Kistner RL, Masuda EM, Sato DT. Risk factors for venous thromboembolism following prolonged air travel. Coach class thrombosis. Hematology/Oncology Clinics of North America 2000;14(2):391-400.
2. Backos M, Rai R, Thomas E, Murphy M, Doré C, Regan L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Human Reproduction 1999;14:2876-80. [DOI: 10.1093/humrep/14.11.2876]
3. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Medical Weekly 2009;139:60-4.
4. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Human Reproduction 2004;19(5):1211-4.
5. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. Journal of Maternal-Fetal Medicine 2000;9(2):122-5.
6. Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology 2006;195:1109-13.
7. Chan GM, McElligott K, McNaught T, Gill G. Effects of dietary calcium intervention on adolescent mothers and newborns: a randomized controlled trial. Obstetrics & Gynecology 2006;108(3 Pt 1):565-71.
8. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. New England Journal of Medicine 2004;350:1914-5.
9. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy-how safe are they?. Current Opinion in Obstetrics & Gynecology 2007;19:573-7.
10. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
11. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thrombosis and Haemostasis 2007;97:496-7.
12. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. British Journal of Surgery 2005;92:177-83.
13. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25:3443-57.
14. Harenberg T. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thrombosis Research 2007;119:385-8.
15. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
16. James AH. Prevention and management of venous thromboembolism in pregnancy. American Journal of Medicine 2007;120:S26-S34.
17. Janakiraman V, Ettinger A, Mercado-Garcia A, Hu H, Hernandez-Avila M. Calcium supplements and bone resorption in pregnancy: a randomized crossover trial. American Journal of Preventive Medicine 2003;24(3):260-4. [DOI: 10.1016/S0749-3797(02)00641-4]
18. Kurabayashi T, Tomita M, Matsushita H, Yahata T, Honda A, Takakuwa K, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. American Journal of Obstetrics and Gynecology 1999;180(5):1115-20. [DOI: 10.1016/S0002-9378(99)70603-4]
19. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology 1996;174:1584-9.
20. Le Templier G, Rodger MA. Heparin-induced osteoporosis and pregnancy. Current Opinion in Pulmonary Medicine 2008;14:403-7.
21. Lefkou E, Khamashta M, Hampson G, Hunt BJ. Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?. Lupus 2009;19(1):3-12. [DOI: 10.1177/0961203309353171]
22. Marik PE, Plante LA. Venus thromboembolic disease and pregnancy. New England Journal of Medicine 2008;360:639-40.
23. Masamoto H, Toma T, Sakumoto K, Kanazawa K. Clearance of antiphospholipid antibodies in pregnancies treated with heparin. Obstetrics & Gynecology 2001;97:394-8.
24. Matziolis G, Perka C, Disch A, Zippel H. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcified Tissue International 2003;73:370-9.
25. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006;108:1569-70.
26. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, et al. Use of low molecular weight heparin in pregnancy. Thrombosis and Haemostasis 1992;68(6):652-6.
27. Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R. The effect of pregnancy on bone density and bone turnover. Journal of Bone and Mineral Research 2000;15(1):129-37. [DOI: 10.1359/jbmr.2000.15.1.129]
28. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. American Journal of Obstetrics and Gynecology 1997;176(5):1062-8. [DOI: 10.1016/S0002-9378(97)70403-4]
29. Ní Ainle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, et al. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagulation and Fibrinolysis 2008;19:573-7.
30. Pettilä V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis 2002;87(2):182-6.
31. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.
32. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
33. Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. Journal of Thrombosis and Haemostasis 2007;5(8):1600-6. [DOI: 10.1111/j.1538-7836.2007.02634.x]
34. Salari P, Rezaie A, Larijani B, Abdollahi M. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Medical Science Monitor 2008;14:37-44.
35. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367(9527):2010-8. [DOI: 10.1016/S0140-6736(06)68891-0]
36. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. European Journal of Obstetrics & Gynecology and Reproductive Biology 1996;65(2):2171-4. [DOI: 10.1016/0301-2115(95)02358-5]
37. Sunyecz JA. The use of calcium and vitamin D in the management of osteoporosis. Therapeutics and Clinical Risk Management 2008;4:827-36.